We tested the feasibility of using a novel contrast agent, MS-325, as a marker of coagulating tissue during thermoablative treatment.
Materials and Methods:
In vivo, we created coagulated lesions in porcine muscle tissue under 3 different conditions: MS-325 (n = 5), gadolinium-DTPA (n = 5), or no contrast agent (n = 9) present during laser thermoablation. At the same time, we performed continuous T1-weighted magnetic resonance imaging at 1.5 T. We quantified the change in signal intensity during treatment expressed as relative enhancement, and compared the 3 groups by using Mann–Whitney analysis.
MS-325 resulted in a more than 3.2-fold increase in relative enhancement over the gadolinium-DTPA and noncontrast control groups (P < 0.008).
MS-325 appears to be a valid marker for coagulating tissue and significantly increased relative enhancement of the treated lesions when compared with both Gd-DTPA and noncontrast-enhanced conditions. MS-325 thus has potential for monitoring of thermoablative treatment.